Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Biogen Idec ( BIIB) upgraded at RBC from Sector Perform to Outperform, RBC Capital said. $75 price target. New analyst expects Tysabri to perform above consensus expectations.

Celgene ( CELG) downgraded at RBC from Outperform to Sector Perform, RBC Capital said. $55 price target. Valuation call, as the stock is already pricing in solid 2011 growth.

Chesapeake Energy ( CHK) upgraded at Canaccord from Hold to Buy, Canaccord Genuity said. $49 price target. Company is improving capital productivity and realizing higher gas prices.

Ciena ( CIEN) rated new Outperform at Wells Fargo. Company is leveraged to a multi-year optical upgrade cycle.

Celestica ( CLS) upgraded at Collins Stewart from Neutral to Buy, Collins Stewart said. $15 price target. Company is turning its business around and winning new customers.

Flextronics ( FLEX) upgraded at Collins Stewart from Neutral to Buy, Collins Stewart said. $11 price target. Company can deliver double-digit growth in each of the next two years.

Fluor ( FLR) upgraded at BMO from Underperform to Market Perform, BMO Capital said. $66 price target. Company has a solid balance sheet, and can absorb losses from two fixed-price contracts.

Netease.com ( NTES) upgraded at Brean Murray from Hold to Buy, Brean Murray said. $54 price target. Company is seeing higher demand across the board.

Ormat Technologies ( ORA) downgraded at Baird to Neutral from Outperform, Robert Baird said. $24 price target. Company lowered its guidance, because of rising costs.

Oracle ( ORCL) rated new Hold at ThinkEquity. $35 price target. Stock is already pricing in solid near-term growth.

Quanta Services ( PWR) downgraded at Deutsche Bank to Hold. $22 price target. Valuation call, as the stock is up 26% over the past three months.

Regeneron Pharmaceuticals ( REGN) upgraded at RBC from Sector Perform to Outperform, RBC Capital said. $48 price target. Company continues to price solid clinical data.

Red Hat ( RHT) downgraded at JP Morgan from Neutral to Underweight. $32 price target. Valuation call, as the stock is already pricing in healthy free cash flow growth.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

European Pharma Companies Slip on MS Pricing Probe

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire